Targeted therapies in rheumatology
Read Online
Share

Targeted therapies in rheumatology

  • 458 Want to read
  • ·
  • 69 Currently reading

Published by Martin Dunitz, Distributed in the USA by Taylor & Francis in London, New York, Independence, KY .
Written in English

Subjects:

  • Rheumatic Diseases -- therapy,
  • Biological Products -- therapeutic use

Book details:

Edition Notes

Includes bibliographical references and index.

Statement[edited by] Josef S. Smolen, Peter E. Lipsky.
ContributionsSmolen, Josef S., 1950-, Lipsky, Peter E.
The Physical Object
Paginationxxi, 729 p. :
Number of Pages729
ID Numbers
Open LibraryOL21486816M
ISBN 101841841579
OCLC/WorldCa50101082

Download Targeted therapies in rheumatology

PDF EPUB FB2 MOBI RTF

Targeted therapies of rheumatic diseases have become a reality and have completely changed patient care as well as patient expectations. Initial success with therapies aimed at blocking TNF and IL-1 has stimulated the development of additional targeted approaches focused on other cytokines as well as specific cells and pathways involved in the pathogenesis of rheumatic with the Price: $ Targeted Therapies in Rheumatology [Smolen, Josef S., Lipsky, Peter E] on *FREE* shipping on qualifying offers. Targeted Therapies in RheumatologyCited by: Book Description. Targeted therapies of rheumatic diseases have become a reality and have completely changed patient care as well as patient expectations. Initial success with therapies aimed at blocking TNF and IL-1 has stimulated the development of additional targeted approaches focused on other cytokines as well as specific cells and. Targeted therapies for patients with rheumatoid arthritis 01 August, By NT Contributor Rheumatoid arthritis (RA) is an auto-immune disease that results in a debilitating inflammatory arthritis with no .

ISBN: OCLC Number: Description: xxi, pages: illustrations ; 25 cm: Responsibility: [edited by] Josef S. Smolen, Peter E. Lipsky.   In the past decade, initiated by the introduction of TNF and IL-1 inhibition, the evolution of therapeutic strategies in rheumatology has left the area of unspecific targeting of pro-inflammatory and immunosuppressive pathways towards a more ‘surgical type’ of therapeutic regimen, the so-called targeted therapies. In this novel book Author: U. Müller-Ladner. Wnt signaling for targeted therapies in rheumatology \/ Kathleen T. Rousche, Dolores Baksh and Rocky S. Tuan -- Inflammatory mediators: update on cyclooxygenases and prostaglandin synthases \/ Leslie J. Crofford, Mohit Kapoor and Fumiaki Kojima --   Targeted Therapies in Rheumatology Barry Bresnihan, MD. Article, Author, and Disclosure Information Hardcover book. Audience: Rheumatologists, pediatric rheumatologists, allergy and immunology physicians, and policymakers. Specific chapters will appeal to gastroenterologists, dermatologists, and neurologists. information is provided on Author: Barry Bresnihan.

Targeted Therapies in Rheumatology established itself as an excellent reference for all those needing to know about the clinical implications of new drugs and developments for patients suffering from rheumatoid arthritis. This volume takes up the further developments that have occurred in several of the drug therapies covered in the first. Targeted therapies of rheumatic diseases have become a reality and have completely changed patient care as well as patient expectations. Initial success with therapies aimed at blocking TNF and IL-1 has stimulated the development of additional targeted approaches focused on other cytokines as well as specific cells and pathways involved in the pathogenesis of rheumatic with the. Targeted Treatment of the Rheumatic Diseases takes a patient management approach to treating adult and pediatric patients with rheumatic diseases. Michael H. Weisman, Michael Weinblatt, James S Louie, and Ronald Van Vollenhoven offer their unique insights into choosing the correct pharmacological and non-pharmacological therapies for your patients. Contemporary Targeted Therapies in Rheumatology. Josef S. Smolen. Targeted therapies of rheumatic diseases have become a reality and have completely changed patient care as well as patient expectations. Initial success with therapies aimed at blocking TNF and IL-1 has stimulated the development of additional targeted approaches focused on other.